Responses
Clinical/translational cancer immunotherapy
Original research
Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial
Compose a Response to This Article
Other responses
No responses have been published for this article.
